European Medical Solutions (LTS:0RGO) Interest Expense : €-0.43 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is European Medical Solutions Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. European Medical Solutions's interest expense for the six months ended in Dec. 2023 was € -0.24 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.43 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. European Medical Solutions's Operating Income for the six months ended in Dec. 2023 was € -0.88 Mil. European Medical Solutions's Interest Expense for the six months ended in Dec. 2023 was € -0.24 Mil. European Medical Solutions did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

European Medical Solutions Interest Expense Historical Data

The historical data trend for European Medical Solutions's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Medical Solutions Interest Expense Chart

European Medical Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.21

-0.50

-0.20

-0.24

-0.43

European Medical Solutions Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.14	-0.04	-0.20	-0.20	-0.24

European Medical Solutions Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.43 Mil.

European Medical Solutions (LTS:0RGO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

European Medical Solutions's Interest Expense for the six months ended in Dec. 2023 was €-0.24 Mil. Its Operating Income for the six months ended in Dec. 2023 was €-0.88 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was €11.86 Mil.

European Medical Solutions's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

European Medical Solutions did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. DMS Imaging SAs earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.

European Medical Solutions (LTS:0RGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » European Medical Solutions (LTS:0RGO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AS0:Germany ALEMS:Belgium

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

European Medical Solutions (LTS:0RGO) Headlines

No Headlines